Free Trial

Achilles Therapeutics Q4 2023 Earnings Report

Achilles Therapeutics logo
$0.98 0.00 (0.00%)
(As of 12/20/2024 05:31 PM ET)

Achilles Therapeutics EPS Results

Actual EPS
-$0.46
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Achilles Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Achilles Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Amazon coin set to soar 25X – starting December 16th? (Ad)

This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024

>3-Cent Amazon Coin<

Achilles Therapeutics Earnings Headlines

Amazon coin set to soar 25X – starting December 16th?
This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024
Achilles Therapeutics reports Q3 EPS (48c) vs. (42c) last year
See More Achilles Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Achilles Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Achilles Therapeutics and other key companies, straight to your email.

About Achilles Therapeutics

Achilles Therapeutics (NASDAQ:ACHL), a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

View Achilles Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings